Clinical trials have shown a decrease in Alzheimer's disease progression by more than half

Phase III clinical trials in patients with mild to moderate Alzheimer's disease have more than halved the progression of the disease. Therapy included removal of β-amyloid from the blood, not from the brain. The levels of β-amyloid are dynamic, and there is a balance between its amount in the brain and in the blood. Past trials have shown that reducing the level of β-amyloid in the blood can reduce its presence in the brain, which is the result of a new equilibrium.

The test seems to be an important confirmation of the amyloid hypothesis of Alzheimer's disease, just at the time of its intense criticism. The history of unsuccessful attempts to reduce β-amyloid levels led to a variety of competing initiatives and increased attention to tau aggregation as the main cause of pathology in the later stages of the disease. I also see in the test some signs in favor of the concept of impaired filtration of CSF in the brain . In it, the ways in which CSF leaves the brain atrophy with age, and the rate of cleaning of metabolic debris decreases.

Alzheimer Management by Albumin Replacement (AMBAR) is an international, multi-center, randomized , blind , placebo-controlled , parallel group clinical trial involving Alzheimer's and Mild Patients from 41 centers in Europe and the United States. The purpose of the test was to evaluate the efficacy and safety of short-term plasma replacement, and then long-term plasmapheresis with injections of human albumin in combination with intravenous infusion of immunoglobulin in patients with mild and moderate Alzheimer's disease.

AMBAR is based on the hypothesis that most β-amyloid accumulated in the brain of Alzheimer's patients is bound to albumin and circulates in plasma. Removing this plasma can lead to the migration of β-amyloid from the brain to the plasma, which reduces the effect of the disease on the cognitive functions of the patient. In addition, albumin can be a comprehensive approach to the treatment of the disease due to its binding ability, antioxidant, immunomodulating and anti-inflammatory properties.
')
The AMBAR trial included 496 patients with mild and moderate Alzheimer's disease, randomized in the three treated groups and one placebo group . The participants were 55-85 years old, and the effectiveness of the treatment was measured by changes in cognition and in terms of daily life. An independent research organization (CRO) controlled the clinical trial and the steps of collecting and analyzing information. Randomized and double-blind controls were used in the trial, which meant that patients, doctors, and examiners did not know whether the patients used treatment or placebo.

AMBAR analyzes have shown positive, very relevant results in patients with moderate Alzheimer's disease. Doctors found a reduction in progression of 50-75% in the cognitive scale of Alzheimer's disease ( ADAS-Cog ) and 42-70% in the scale of daily living ( ADCS-ADL ) in patients receiving treatment. Including all patients receiving plasma replacement, the difference was 66% for the ADAS-Cog scale and 52% for the ADCS-ADL scale.

www.grifols.com/en/view-news/-/new/grifols-ambar-results-demonstrate-a-significant-reduction-in-the-progression-of-moderate-alzheimers-disease